Report: The Complete Guide to Targeted Therapies in Oncology: A World Review TOC

1 Executive Summary

2 Table of Contents

2.1 List of Boxes
2.2 List of Figures
2.3 List of Tables

3 Methodology

4 Introduction to Apoptosis in Oncology

5 Apoptosis Competitive Landscape in Oncology

5.1 Countries & Players: Who are In the Lead?
- 5.1.1 Top 10 Players Dominate The Developmental Pipeline
5.2 Deals & Alliances in Apoptosis Drug Development
- 5.2.1 Review of Deals and Alliances Initiated in 2006
- 5.2.2 Review of Deals and Alliances Initiated in 2005
- 5.2.3 Review of Deals and Alliances Initiated in 2004
- 5.2.4 Review of Deals and Alliances Initiated in 2003
- 5.2.5 Review of Deals and Alliances Initiated in 2002
- 5.2.6 Review of Deals and Alliances Initiated in 2001

6 Approved Apoptopic Cancer Drugs: Performance

7 Target Analysis in Apoptosis

7.1 Targets of Late Stage Apoptopic Drugs in Development
- 7.1.1 B-cell CLL/lymphoma 2
- 7.1.2 Caspase 3
- 7.1.3 CD4 molecule
- 7.1.4 Cytosolic ovarian carcinoma antigen 1
- 7.1.5 Eukaryotic translation elongation factor 2
- 7.1.6 Farnesyltransferase, CAAX box, alpha
- 7.1.7 Fc fragment of IgE
- 7.1.8 Histone deacetylase 1
- 7.1.9 Histone deacetylase 2
- 7.1.10 Interleukin 13 receptor, alpha 1
- 7.1.11 Phosphodiesterase 2A, cGMP-stimulated
- 7.1.12 Phosphodiesterase 5A, cGMP-specific
- 7.1.13 Protein kinase C, beta 1
- 7.1.14 Steroid 5-alpha-reductase, alpha polypeptide 1
- 7.1.15 Topoisomerase (DNA) I
- 7.1.16 Topoisomerase (DNA) II alpha
- 7.1.17 Tubulin, beta polypeptide
- 7.1.18 p53 protein
7.2 Apoptopic Drugs and Their Targets According to Top 5 Cancer Indications
- 7.2.1 Targets in Breast Cancer
- 7.2.2 Targets in Leukemia
- 7.2.3 Targets in Lung Cancer
- 7.2.4 Targets in Lymphoma
- 7.2.5 Targets in Prostate Cancer

8 Apoptopic Drugs in Development: By Major Indications

8.1 General Drug Developmental Overview
- 8.1.1 Apoptopic Drugs in Phase III Clinical Development
- 8.1.2 Failed Apoptopic Drugs in Oncology
8.2 Progress Analysis - Breast Cancer
- 8.2.1 Phase I Clinical Development
- 8.2.2 Phase II Clinical Development
- 8.2.3 Phase III Clinical Development
8.3 Progress Analysis - Leukemia
- 8.3.1 Phase I Clinical Development
- 8.3.2 Phase II Clinical Development
- 8.3.3 Phase III Clinical Development
8.4 Progress Analysis - Lung Cancer
- 8.4.1 Phase I Clinical Development
- 8.4.2 Phase II Clinical Development
- 8.4.3 Phase III Clinical Development
8.5 Progress Analysis - Lymphoma
- 8.5.1 Phase I Clinical Development
- 8.5.2 Phase II Clinical Development
- 8.5.3 Phase III Clinical Development
8.6 Progress Analysis - Prostate Cancer
- 8.6.1 Phase I Clinical Development
- 8.6.2 Phase II Clinical Development
- 8.6.3 Phase III Clinical Development

9 Protein Kinase Inhibitors

9.1 Rationale for Development of Kinase Inhibitors in Oncology
9.2 Protein Kinase Targets - A Growing Family
9.3 Challenges in Protein Kinase Drug Discovery
- 9.3.1 Enabling Structure-Based Drug Design is the Key
- 9.3.2 Specific Kinase Inhibitors without Kinase Profiling?
9.4 Drugs according to Target
- 9.4.1 Cyclin-dependent Kinase Target Inhibitors
- 9.4.2 Aurora Kinase Target Inhibitors
- 9.4.3 Cell Cycle Checkpoint Target Controls Inhibitors
- 9.4.4 Tyrosine Kinase Receptor Inhibitors
- 9.4.5 Other Serine/Threonine Kinase Target Inhibitors
9.5 Dual or Multiple Kinase Inhibitor Analysis
- 9.5.1 Presentation of Drugs Targeting A to F Kinases
- 9.5.2 Presentation of Drugs Targeting G to T Kinases
9.6 Targets According to Indication
- 9.6.1 Breast Cancer
- 9.6.2 Prostate Cancer: What Cannot be Found in the ' Groins' ?
- 9.6.3 Lung Cancer: A Need for Improved Survival Rates
- 9.6.4 Colorectal Cancer: EGFR & VEGFR are Strong Targets but There are Others
- 9.6.5 Leukemia: Show Me the Power of PKI
- 9.6.6 Melanoma
- 9.6.7 Lymphoma: We Are In
9.7 Growing Competition in the Field
9.8 Big Pharma Outlook: The Race is On
- 9.8.1 Novartis Deals - Digs Deeper into Cell Cycle Inhibitors
- 9.8.2 AstraZeneca - Wheeling and Dealing
- 9.8.3 Pfizer' s Long Look at OSI Pharmaceuticals
- 9.8.4 GlaxoSmithKline Gains Momentum
9.9 Strategic Deals Creating Competitive Edge
- 9.9.1 Mergers
- 9.9.2 Astex - the PKI Switchboard
- 9.9.3 Big Pharma' s Darling
9.10 Current Protein Kinase Inhibitors in Therapy
- 9.10.1 Mechanism, Target and Developmental History
- 9.10.2 Approvals: Indications & Markets
9.11 Protein Kinase Inhibitors in Drug Development - A Progress Analysis
- 9.11.1 Progress Analysis - Breast Cancer
- 9.11.2 Progress Analysis - Prostate Cancer
- 9.11.3 Progress Analysis - Lung Cancer
- 9.11.4 Progress Analysis - Colorectal Cancer
- 9.11.5 Progress Analysis - Leukemia
- 9.11.6 Progress Analysis - Melanoma
- 9.11.7 Progress Analysis - Lymphoma

10 Anti-Angiogenesis & Vascular Targeting

10.1 Neoplastic Angiogenesis & Tumor Vasculature
- 10.1.1 Tumor Vasculature
- 10.1.2 The Current Model of Sprouting Angiogenesis
10.2 Main Angiogenic Factors
- 10.2.1 Vascular Endothelial Growth Factor
- 10.2.2 The Angiopoietins and Platelet Derived Growth Factor
- 10.2.3 Integrins in Angiogenesis
- 10.2.4 Inhibitors of Angiogenesis
10.3 Vascular Targeting Agents
10.4 Vascular Disruptive Agents
10.5 Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology
10.6 Countries & Players: Who are In the Lead?
- 10.6.1 Top 10 Players Dominate The Developmental Pipeline
10.7 Deals & Alliances in Anti-Angiogenesis and Vascular Targeting
- 10.7.1 Review of Deals and Alliances Initiated in 2005
- 10.7.2 Review of Deals and Alliances Initiated in 2004
- 10.7.3 Review of Deals and Alliances Initiated in 2003
10.8 Approved Anti-Angiogenic Cancer Drugs: Performance
10.9 Target Analysis in Anti-Angiogenesis and Vascular Targeting
10.10 Targets of Late Stage Anti-Angiogenic Drugs in Development
- 10.10.1 Drugs with Epidermal Growth Factor Receptor as a Target
- 10.10.2 Drugs with FMS-related Tyrosine Kinase 1 as a Target
- 10.10.3 Drugs with FMS-related Tyrosine Kinase 4 as a Target
- 10.10.4 Drugs with Kinase Insert Domain Receptor as a Target
- 10.10.5 Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
- 10.10.6 Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
- 10.10.7 Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
- 10.10.8 Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
- 10.10.9 Drugs with Protein Kinase C, beta 1 as a Target
- 10.10.10 Drugs with Ret Proto-Oncogene as a Target
- 10.10.11 Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
- 10.10.12 Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
- 10.10.13 Drugs with Vascular Endothelial Growth Factor as a Target
10.11 Anti-Angiogenic Drugs and Their Targets According to Top 5 Cancer Indications
- 10.11.1 Targets in Breast Cancer
- 10.11.2 Targets in Colorectal Cancer
- 10.11.3 Targets in Lung Cancer
- 10.11.4 Targets in Prostate Cancer
- 10.11.5 Targets in Renal Cancer
10.12 Anti-angiongenesis and Vascular Targeting Drugs in Development: By Major Indications
10.13 General Drug Developmental Overview
10.14 Progress Analysis - Breast Cancer
- 10.14.1 Phase I Clinical Development
- 10.14.2 Phase II Clinical Development
- 10.14.3 Phase III Clinical Development
10.15 Progress Analysis - Colorectal Cancer
- 10.15.1 Phase I Clinical Development
- 10.15.2 Phase II Clinical Development
- 10.15.3 Phase III Clinical Development
10.16 Progress Analysis - Lung Cancer
- 10.16.1 Phase I Clinical Development
- 10.16.2 Phase II Clinical Development
- 10.16.3 Phase III Clinical Development
10.17 Progress Analysis - Prostate Cancer
- 10.17.1 Phase I Clinical Development
- 10.17.2 Phase II Clinical Development
- 10.17.3 Phase III Clinical Development
10.18 Progress Analysis - Renal Cancer
- 10.18.1 Phase I Clinical Development
- 10.18.2 Phase II Clinical Development
- 10.18.3 Phase III Clinical Development

11 Immunotherapy in Oncology

11.1 Vaccine Strategies: Challenges & Opportunities
11.2 Key Antibody Developmental Strategies

12 Competitive Landscape in Cancer Vaccines

12.1 Countries & Players: Who are In the Lead?
- 12.1.1 Top 10 Players Constitute Up to One Third of R&D: Big Pharma Not Included!
- 12.1.2 Approved Cancer Vaccine Drugs: Performance
12.2 Deals & Alliances in Cancer Vaccines
- 12.2.1 Recent Mergers & Acquisitions in Cancer Vaccines
- 12.2.2 Deals in Prostate Cancer
- 12.2.3 Deals in Breast Cancer
- 12.2.4 Deals in Leukemia & Lymphoma
- 12.2.5 Drug Delivery Deals in Cancer Vaccines
- 12.2.6 Adjuvant Deals

13 Antibody Deals on the Rise

13.1 Antibody Deals in Phase III
- 13.1.1 Deal Situation: MDX 010
- 13.1.2 Deal Situation: WX G250
- 13.1.3 Deal Situation: Zanolimumab
13.2 Antibody Deals in Phase II
- 13.2.1 Deal Situation: Mapatumumab
- 13.2.2 Deal Situation: GCR 3888
- 13.2.3 Deal Situation: MDX 070
- 13.2.4 Deal Situation: CDP 860
- 13.2.5 Deal Situation: Tru-Scint OV
- 13.2.6 Deal Situation: SC 1
- 13.2.7 Deal Situation: PRO 70769
- 13.2.8 Deal Situation: XR 303
- 13.2.9 Deal Situation: HumaRAD-HN

14 Tumor Antigens

14.1 Tumor Antigens: General Comments
14.2 Antigen Discovery
- 14.2.1 Classical Immunology Approach
- 14.2.2 The Reverse Immunology Approach
- 14.2.3 Company Platforms
14.3 Specific Antigen Processing Technologies Increasing Antigen Presentation

15 Immunomodulators & Adjuvants in Cancer Vaccines

15.1 Overview
15.2 Cytokines
- 15.2.1 Vaccines in Combination with Interleukin-2
- 15.2.2 Tumor Necrosis Factor
- 15.2.3 Interferons
15.3 Adjuvants
15.4 Other Immunomodulating Strategies
- 15.4.1 An Immune Response Modifying Protein
- 15.4.2 Immunostimulatory DNA
- 15.4.3 Ex Vivo Stimulated Immune Cells
- 15.4.4 Fusion Protein Gain Potent Immune Response
- 15.4.5 Macrophage and Natural Killer Cells Activation
- 15.4.6 Selective Suppression of the Immune System to An Antigen
- 15.4.7 TAP Technology

16 Cancer Vaccine Delivery

16.1 Viral Delivery
- 16.1.1 Introduction
- 16.1.2 Viral Constructs Put into Use
16.2 Bacterias
16.3 Cell Therapy: Dendritic-cell Based & Cancer-Cell Based Therapies
- 16.3.1 Introduction
- 16.3.2 Cell Therapy Strategies
16.4 Synthetic Delivery Systems & Strategies
- 16.4.1 Introduction
- 16.4.2 Biotransport™
- 16.4.3 Biotype®vector
- 16.4.4 DNAVax Gene Delivery System
- 16.4.5 FusitAb™
- 16.4.6 GeneDrug™
- 16.4.7 Molecular Conjugates
- 16.4.8 Naked DNA Delivery
- 16.4.9 PVLP Technology
- 16.4.10 Sphingosomal Drug Delivery Technology
- 16.4.11 STEALTH
- 16.4.12 Failed Liposomal Systems

17 New Approaches in Antibody Delivery and Design - The Next Generation

17.1 How to Make Them Smaller and Different?
17.2 Biomaterials in Sustained Delivery Applications
- 17.2.1 Implants
17.3 Gene delivery - the Future?
- 17.3.1 Delivery Vehicles for DNA
- 17.3.2 Gene Delivery in Commercialization

18 Cancer Vaccines in Development: By Major Indications

18.1 General Oncology Overview
18.2 Progress Analysis - Melanoma
18.3 Progress Analysis - Breast Cancer
18.4 Progress Analysis - Prostate Cancer
18.5 Progress Analysis - Lung Cancer
18.6 Progress Analysis - Colorectal Cancer
18.7 Progress Analysis - Cervical Cancer

19 Antibodies in Clinical Development

19.1.1 Prostate Cancer Therapeutics
19.1.2 Breast Cancer Therapeutics
19.1.3 Colorectal Cancer Therapeutics
19.1.4 Melanoma Therapeutics
19.1.5 Hematological Cancers Therapeutics

19.2 Antibodies in Phase III Clinical Development
- 19.2.1 Progress Analysis: IGN 101
- 19.2.2 Progress Analysis: MDX 010
- 19.2.3 Progress Analysis: ONYVAX 105
- 19.2.4 Progress Analysis: Ovarex
- 19.2.5 Progress Analysis: Panitumumab
- 19.2.6 Progress Analysis: RENCAREX
- 19.2.7 Progress Analysis: Nimotuzumab
- 19.2.8 Progress Analysis: TransMID
- 19.2.9 Progress Analysis: Lintuzumab
- 19.2.10 Progress Analysis: Zanolimumab
19.3 Antibodies in Phase II Clinical Development
- 19.3.1 Progress Analysis: ABT-510
- 19.3.2 Progress Analysis: BB 10901
- 19.3.3 Progress Analysis: CP 675206
- 19.3.4 Progress Analysis: CNTO-328
- 19.3.5 Progress Analysis: Ecromeximab
- 19.3.6 Progress Analysis: EMD 273063
- 19.3.7 Progress Analysis: WX-G250RIT
- 19.3.8 Progress Analysis: HGS-ETR1
- 19.3.9 Progress Analysis: HuMax-CD20
- 19.3.10 Progress Analysis: HuMax-EGFr
- 19.3.11 Progress Analysis: Galiximab
- 19.3.12 Progress Analysis: PROXINIUM
- 19.3.13 Progress Analysis: RAV12
- 19.3.14 Progress Analysis: SGN-15
- 19.3.15 Progress Analysis: SGN-30
- 19.3.16 Progression Analysis: VEGF-Trap
- 19.3.17 Progress Analysis: MEDI 522
- 19.3.18 Progress Analysis: Volociximab

20 Disclaimer

21 Appendix I: Complete List of Apoptopic Drugs in Development in Oncology

22 Appendix II: Complete List of Angiogenic and Vascular Target Agents in Development in Oncology

23 Company Index

24 Drug Index

List of Boxes

Box 1: Business & Market - PXD-101
Box 2: Business & Market - MG-98
Box 3: Business & Market - VX-680
Box 4: Business & Market - Ceflatonin
Box 5: Business & Market - Oblimersen sodium
Box 6: Business & Market - motexafin gadolinium
Box 7: Business & Market - 1D09C3
Box 8: Business & Market - PCK-3145
Box 9: Business & Market - ME-2
Box 10: The Power of Ambit' s Kinase Profiling
Box 11: Summary Terms of the Exelixis Transaction
Box 12: Nexavar' s Clinical Data That Lead To Its EMEA Approval Myeloma
Box 13: Thalomid Delays Time to Disease Progression in Newly Diagnosed Multiple Myeloma
Box 14: Strong Clinical Data Suggests Approval to Market Avastin For The Treatment of Both Breast Cancer and NSCLC
Box 15: Avastin Fails to Meet Primary Endpoint in Advanced Pancreatic Cancer
Box 16: Business & Market - Cilengitide
Box 17: Business & Market - Exherin
Box 18: Business & Market - WX-UK1
Box 19: Business & Market - Combretastatin A-4 phosphate
Box 20: Business & Market - GCS-100LE
Box 21: Business & Market - PTK/ZK
Box 22: Business & Market - AS-1404
Box 23: Business & Market - Phosphomannopentaose sulfate
Box 24: Business & Market - Squalamine
Box 25: Business & Market - talactoferrin alfa
Box 26: Business & Market - ZD-6474
Box 27: Business & Market - AP-23573
Box 28: Business & Market - Volociximab
Box 29: Business & Market - XL-999
Box 30: Mechanisms Which Tumor Cells Use to Evade an Immune Reaction
Box 31: M-VAX - Business & Market Bakground
Box 32: Gardasil: Business & Market Background
Box 33: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology
Box 34: TNF in Cancer Treatments
Box 35: Marrion' s Drug Delivery Technology
Box 36: Quick Facts - IGN 101
Box 37: Quick Facts - MDX 010
Box 38: Quick Facts - ONYVAX 105
Box 39: Quick Facts - Ovarex
Box 40: Quick Facts - Panitumumab
Box 41: Quick Facts - RENCARNEX
Box 42: Quick Facts - Nimotuzumab
Box 43: Quick Facts - RENCARNEX
Box 44: Quick Facts - Lintuzumab
Box 45: Quick Facts - Zanolimumab
Box 46: Quick Facts - ABT-510
Box 47: Quick Facts - BB 10901
Box 48: Quick Facts - CP-675206
Box 49: Quick Facts - CNTO-328
Box 50: Quick Facts - Ecromeximab
Box 51: Quick Facts - EMD-273063
Box 52: Quick Facts - WX-G250RIT
Box 53: Quick Facts - HGS-ETR1
Box 54: Quick Facts - HuMax-CD20
Box 55: Quick Facts - HuMax-EGFr
Box 56: Quick Facts - Galiximab
Box 57: Quick Facts - PROXINIUM
Box 58: Quick Facts - RAV12
Box 59: Quick Facts -SGN-15
Box 60: Quick Facts -SGN-30
Box 61: Quick Facts - VEGF-Trap
Box 62: Quick Facts - MEDI 522
Box 63: Quick Facts - Volociximab

List of Figures

Figure 1: Top 5 Countries in Apoptopic Cancer Research
Figure 2: Top 10 Companies' Clinical Trial Progress in Apoptopic Drug Development
Figure 3: Trial Distribution of the Entire Apoptopic Pipeline in Oncology
Figure 4: Distribution of ApoptopicTrials in Breast Cancer
Figure 5: Distribution of Apoptopic Drug Trials in Leukemia
Figure 6: Distribution of Apoptopic Drug Trials in Lung Cancer
Figure 7: Distribution of Apoptopic Drug Trials in Lymphoma
Figure 8: Distribution of Apoptopic Drug Trials in Prostate Cancer
Figure 9: Top 10 PKI Drug Developing Companies
Figure 10: Clinical Trial Distribution in Breast Cancer for PKI Drugs
Figure 11: Clinical Trial Distribution in Prostate Cancer for PKI Drugs
Figure 12: Clinical Trial Distribution in Lung Cancer for PKI Drugs
Figure 13: Clinical Trial Distribution in Colorectal Cancer for PKI Drugs
Figure 14: Clinical Trial Distribution in Leukemia for PKI Drugs
Figure 15: Clinical Trial Distribution in Melanoma for PKI Drugs
Figure 16: Clinical Trial Distribution in Lymphoma for PKI Drugs
Figure 17: Establishment of Blood Supply to Tumors
Figure 18: Sprouting Angiogenesis
Figure 19: Top 5 Countries in Cancer Angiogenesis and Vascular Targeting Research
Figure 20: Top 10 Companies' Clinical Trial Progress in Anti-Angiogenesis and Vascular Targeting
Figure 21: Deals & Alliances in Anti-Angiogenesis and Vascular Targeting 2001-2005
Figure 22: Annual Sales of Avastin on US and Non US Markets
Figure 23: Trial Distribution of the Entire Anti-Angiogenic and Vascular Target Agent Field in Oncology
Figure 24: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Breast Cancer
Figure 25: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Colorectal
Figure 26: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Lung Cancer
Figure 27: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Prostate Cancer
Figure 28: Distribution of Anti-Angiogensis & Vascular Targeting Trials in Renal Cancer
Figure 29: Top 10 Countries in Cancer Vaccine Research
Figure 30: Top 10 Companies' Clinical Trial Progress in Cancer Vaccine
Figure 31: 2003-2005 Deals & Alliances in Cancer Vaccine
Figure 32: Distribution of Cancer Vaccine Trials in Melanoma
Figure 33: Distribution of Cancer Vaccine Trials in Breast Cancer
Figure 34: Distribution of Cancer Vaccine Trials in Prostate Cancer
Figure 35: Distribution of Cancer Vaccine Trials in Lung Cancer
Figure 36: Distribution of Cancer Vaccine Trials in Colorectal Cancer
Figure 37: Distribution of Cancer Vaccine Trials in Cervical Cancer

List of Tables

Table 1: Top 10' s Apoptopic Pipeline Drugs
Table 2: Deals & Alliances in Apoptosis Drug Development in Oncology
Table 3: Companies with Apoptopic Cancer Drugs on the Market
Table 4: List of 120 Known Targets in Apoptosis Drug Development
Table 5: Known Targets of Late Stage Apoptopic Drugs Development
Table 6: Drugs with Bcl-2 as a Target
Table 7: Drugs with Casp-3 as a Target
Table 8: Drugs with CD4 molecule as a Target
Table 9: Drugs with Cova-1 as a Target
Table 10: Drugs with Eef-2 as a Target
Table 11: Drugs with Fnta as a Target
Table 12: Drugs with Fcer-2 as a Target
Table 13: Drugs with Hdac-1 as a Target
Table 14: Drugs with Hdac-2 as a Target
Table 15: Drugs with IL13-RA1 as a Target
Table 16: Drugs with Pde-2A as a Target
Table 17: Drugs with Pde-5A as a Target
Table 18: Drugs with Prkcb-1 as a Target
Table 19: Drugs with Srd-5A1 as a Target
Table 20: Drugs with Top-1 as a Target
Table 21: Drugs with Top-2A as a Target
Table 22: Drugs with Top-2A as a Target
Table 23: Drugs with p53 protein as a Target
Table 24: Breast Cancer Targets in Apoptopic Drug Development
Table 25: Leukemia Targets in Apoptopic Drug Development
Table 26: Lung Cancer Targets in Apoptopic Drug Development
Table 27: Lymhoma Targets in Apoptopic Drug Development
Table 28: Prostate Cancer Targets in Apoptopic Drug Development
Table 29: Top 10 Cancer Indications in Apoptopic Cancer Drugs
Table 30: Overview of Apoptopic Drugs in Phase III Clinical Development
Table 31: Recently Ceased or Discountinued Phase I to Phase III Apoptopic Drugs
Table 32: List of Phase I to Phase III Apoptopic Drugs in Development for Breast Cancer
Table 33: List of Phase I to Phase III Apoptopic Drugs in Development for Leukemia
Table 34: List of Phase I to Phase III Apoptopic Drugs in Development for Lung Cancer
Table 35: List of Phase I to Phase III Apoptopic Drugs in Development for Lymphoma
Table 36: List of Phase I to Phase III Apoptopic Drugs in Development for Prostate Cancer
Table 37: Overview of Targets in Commercial Development
Table 38: Cyclin-dependent Kinase Targets in Development
Table 39: Aurora Kinase Targets in Development
Table 40: Cell Cycle Checkpoint Targets in Development
Table 41: Epidermal Growth Factor Receptor Targets in Development
Table 42: FMS-like tyrosine kinases and their Synonyms
Table 43: Fms-related Tyrosine Kinase Targets in Development
Table 44: Platelet-derived Growth Factor Receptor Targets in Development
Table 45: Kinase Insert Domain Targets in Development
Table 46: Drugs in Development Targeting the PI3K/Akt/mTOR pathway
Table 47: Drugs in Development Targeting the Ras-Raf-MEK-ERK (ERK) pathway
Table 48: Serine/Threonine Kinase Inhibitors in Development
Table 49: Protein Kinase Targets in Clinical Trials for Breast Cancer
Table 50: Protein Kinase Targets in Clinical Trials for Prostate Cancer
Table 51: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 52: Protein Kinase Targets in Clinical Trials for Colorectal Cancer
Table 53: Protein Kinase Targets in Clinical Trials for Leukemia
Table 54: Protein Kinase Targets in Clinical Trials for Melanoma
Table 55: Protein Kinase Targets in Clinical Trials for Lymphoma
Table 56: Drugs in Therapy - Mechanism & Targets
Table 57: Current and Developmental History of PKI Drugs in Therapy
Table 58: Approvals: Indications & Markets
Table 59: Top 10 Drugs in Terms of Number of Clinical Trials
Table 60: List of Cancer Indications Targeted by Protein Kinase Inhibitors
Table 61: PKI Drugs in Development for Breast Cancer
Table 62: PKI Drugs in Development for Prostate Cancer
Table 63: PKI Drugs in Development for Lung Cancer
Table 64: PKI Drugs in Development for Colorectal Cancer
Table 65: PKI Drugs in Development for Leukemia
Table 66: PKI Drugs in Development for Melanoma
Table 67: PKI Drugs in Development for Lymphoma
Table 68: Top 10' s Anti-angiogenic and Vascular Targeting Pipeline Drugs
Table 69: Deals & Alliances in 2005
Table 70: Deals & Alliances in 2004
Table 71: Deals & Alliances in 2003
Table 72: Companies with Cancer Anti-angiogenic Drugs on the Market
Table 73: 2006 Q2 Sales Revlimid and Thalomid
Table 74: 2006 Q2 Sales of Avastin
Table 75: List of 75 Known Targets in Ant-angiogenis and Vascular Targeting in Drug Development
Table 76: Known Targets of Late Stage Anti-Angiogenic Drugs in Development
Table 77: Drugs with Epidermal Growth Factor Receptor as a Target
Table 78: Drugs with FMS-related Tyrosine Kinase 1 as a Target
Table 79: Drugs with FMS-related Tyrosine Kinase 4 as a Target
Table 80: Drugs with Kinase Insert Domain Receptor as a Target
Table 81: Drugs with Phosphodiesterase 2A, cGMP-stimulated as a Target
Table 82: Drugs with Phosphodiesterase 5A, cGMP-specific as a Target
Table 83: Drugs with Patelet-Derived Growth Factor Receptor, alpha Polypeptide as a Target
Table 84: Drugs with Platelet-Derived Growth Factor, beta Polypeptide as a Target
Table 85: Drugs with Protein Kinase C, beta 1 as a Target
Table 86: Drugs with Ret Proto-Oncogene as a Target
Table 87: Drugs with v-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog as a Target
Table 88: Drugs with v-raf-1 Murine Leukemia Viral Oncogene Homolog 1 as a Target
Table 89: Drugs with Vascular Endothelial Growth Factor as a Target
Table 90: Breast Cancer Targets in Anti-Angiogenic Drug Development
Table 91: Colorectal Cancer Targets in Anti-Angiogenic Drug Development
Table 92: Lung Cancer Targets in Anti-Angiogenic Drug Development
Table 93: Prostate Cancer Targets in Anti-Angiogenic Drug Development
Table 94: Renal Cancer Targets in Anti-Angiogenic Drug Development
Table 95: Top 10 Cancer Indications in Anti-Angiogenesis and Vascular Targeting Cancer Drugs
Table 96: Recent Ceased or Discountinued Phase I to Phase III Anti-angiogenic and Vascular Targeting Drugs
Table 97: Overview of Drugs in Phase III Clinical Development
Table 98: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Breast Cancer
Table 99: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Colorectal Cancer
Table 100: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Lung Cancer
Table 101: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Prostate Cancer
Table 102: List of Phase I to Phase III Anti-Angiogenesis and Vascular Targeting Agents in Development for Renal Cancer
Table 103: Summary of Strategies Enhancing Antibody Function
Table 104: Companies with Cancer Vaccine Drugs on Market
Table 105: Antigen Classification
Table 106: Platforms Used to Improve Antigen Presentation
Table 107: Cancer Vaccines in Clinical Trials in Combination with Interleukin-2
Table 108: Adjuvants in Cancer Vaccines
Table 109: Synthetic Delivery Systems Deployed in Cancer in General and Cancer Vaccines in Particular
Table 110: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies
Table 111: Drug Delivery Companies with Cancer Focus
Table 112: FDA Approved Polymer-based Drug Delivery Systems for Cancer
Table 113: Top 10 Cancer Indications in Non-Antibody Based Cancer Vaccines
Table 114: Discountinued Phase I to Phase III Cancer Vaccine Drugs
Table 115: List of Phase I to Phase III Cancer Vaccines in Development for Melanoma
Table 116: List of Phase I to Phase III Cancer Vaccines in Development for Breast Cancer
Table 117: List of Phase I to Phase III Cancer Vaccines in Development for Prostate Cancer
Table 118: List of Phase I to Phase III Cancer Vaccines in Development for Lung Cancer
Table 119: List of Phase I to Phase III Cancer Vaccines in Development for Colorectal Cancer
Table 120: List of Phase I to Phase III Cancer Vaccines in Development for Cervical Cancer
Table 121: Antibody Therapeutics in Prostate Cancer
Table 122: Antibody Therapeutics in Breast Cancer
Table 123: Antibody Therapeutics in Colorectal Cancer
Table 124: Antibody Therapeutics in Melanoma
Table 125: Antibody Therapeutics in Hematological Cancer
Table 126: MDX-010' s Collaborative History and Landscape